Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | KDM2B | Q8NHM5 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3179735 | 0.78 | KDM4E (0.44) | GAAKDM2BKDM4EALDH1A1LMNA | |
| N-Methylpiperidine SCHEMBL11353667 | 0.77 | GAA (0.56) | GAAKDM4EALDH1A1LMNAPOLB | |
| SCHEMBL29381201 | 0.77 | KDM4E (0.68) | GAAKDM4EALDH1A1POLBHSD17B10 | |
| SCHEMBL43084 | 0.77 | KDM4E (0.68) | GAAKDM4EALDH1A1POLBHSD17B10 | |
| SCHEMBL8355294 | 0.77 | GAA (0.51) | GAAKDM2BKDM4EALDH1A1LMNA | |
| Ammonia Solution, Strong SCHEMBL1553414 | 0.75 | KDM4E (0.66) | GAAKDM4EALDH1A1POLBHSD17B10 | |
| SCHEMBL14837757 | 0.75 | KDM4E (0.66) | GAAKDM4EALDH1A1POLBHSD17B10 | |
| Hydrochloric Acid SCHEMBL3149083 | 0.75 | KDM4E (0.66) | GAAKDM4EALDH1A1POLBHSD17B10 | |
| SCHEMBL18859030 | 0.75 | KDM4E (0.66) | GAAKDM4EALDH1A1LMNAPOLB | |
| SCHEMBL18859029 | 0.75 | KDM4E (0.66) | GAAKDM4EALDH1A1POLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456192-B2 | 3β-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof | PIERRE FABRE MEDICAMENT (FR) | 2008-11-25 | — | — | US | disclosed |
| US-20050080085-A1 | Novel 3beta-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof | PIERRE FABRE MEDICAMENT (FR) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080085-A1 | Novel 3beta-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof | AOC3, MAOB, AOC1 | GAA 2834/4885KDM2B 1379/4885KDM4E 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.